Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
0%
0%
0.0%
6 Months
0%
0%
0.0%
1 Year
-80.0%
0%
-80.0%
2 Years
-99.99%
0%
-99.99%
3 Years
-100.0%
0%
-100.0%
4 Years
-100.0%
0%
-100.0%
5 Years
-100.0%
0%
-100.0%
ThermoGenesis Holdings, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-2.25%
EBIT Growth (5y)
4.13%
EBIT to Interest (avg)
-0.97
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
3.67
Sales to Capital Employed (avg)
0.98
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
3.79%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
Industry P/E
Price to Book Value
0.00
EV to EBIT
-0.60
EV to EBITDA
-0.75
EV to Capital Employed
0.79
EV to Sales
0.38
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-130.99%
ROE (Latest)
-1361.50%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
Bollinger Bands
Sideways
Sideways
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot : Mar 2024
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 3 Schemes (0.44%)
Foreign Institutions
Held by 3 Foreign Institutions (0.0%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Mar'24 - QoQ
Mar'24
Dec'23
Change(%)
Net Sales
2.70
2.40
12.50%
Operating Profit (PBDIT) excl Other Income
-0.20
-1.90
89.47%
Interest
1.50
3.30
-54.55%
Exceptional Items
0.00
-2.00
100.00%
Consolidate Net Profit
-2.00
-7.60
73.68%
Operating Profit Margin (Excl OI)
-203.50%
-931.80%
72.83%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2024 is 12.50% vs 9.09% in Dec 2023
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2024 is 73.68% vs -105.41% in Dec 2023
Annual Results Snapshot (Consolidated) - Dec'23
Dec'23
Dec'22
Change(%)
Net Sales
9.40
10.50
-10.48%
Operating Profit (PBDIT) excl Other Income
-5.40
-5.30
-1.89%
Interest
10.00
5.60
78.57%
Exceptional Items
-2.40
-0.00
Consolidate Net Profit
-18.90
-11.80
-60.17%
Operating Profit Margin (Excl OI)
-696.00%
-590.80%
-10.52%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2023 is -10.48% vs 12.90% in Dec 2022
Consolidated Net Profit
YoY Growth in year ended Dec 2023 is -60.17% vs 0.84% in Dec 2022
About ThermoGenesis Holdings, Inc. 
ThermoGenesis Holdings, Inc.
Pharmaceuticals & Biotechnology
ThermoGenesis Holdings, Inc., formerly Cesca Therapeutics Inc., develops, commercializes and markets a range of automated technologies for chimeric antigen receptor (CAR)-T and other cell-based therapies. It offers a suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. Its CAR-TXpress platform is its cellular processing platform. It offers cell manufacturing tools and services in the global cell and gene therapy market.
Company Coordinates 
Company Details
2711 Citrus Rd , RANCHO CORDOVA CA : 95742-6228
Registrar Details






